Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.

MLA

Tombling, Benjamin J., et al. “Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.” Journal of Medicinal Chemistry, vol. 64, no. 5, Mar. 2021, pp. 2523–33. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.0c01766.

APA

Tombling, B. J., Lammi, C., Lawrence, N., Gilding, E. K., Grazioso, G., Craik, D. J., & Wang, C. K. (2021). Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor. Journal of Medicinal Chemistry, 64(5), 2523–2533. https://doi.org/10.1021/acs.jmedchem.0c01766

Chicago

Tombling, Benjamin J, Carmen Lammi, Nicole Lawrence, Edward K Gilding, Giovanni Grazioso, David J Craik, and Conan K Wang. 2021. “Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.” Journal of Medicinal Chemistry 64 (5): 2523–33. doi:10.1021/acs.jmedchem.0c01766.